Effect of imatinib mesylate (Gleevec) on anaplastic thyroid carcinoma cell lines

被引：7
|
作者：
Mitsiades, CS
Sykoutri, D
McMullan, C
Poulaki, V
Mitsiades, N
机构：
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[2] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Angiogenesis Lab, Boston, MA 02114 USA
来源：
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM | 2003年 / 88卷 / 10期
关键词：
D O I：
10.1210/jc.2003-030968
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：5043 / 5044
页数：2
相关论文
共 50 条
  • [1] Authors' response: Effect of imatinib mesylate (Gleevec) on anaplastic thyroid carcinoma cell lines
    Podtcheko, A
    Ohtsuru, A
    Namba, H
    Saenko, V
    Yamashita, S
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (10): : 5044 - 5044
  • [2] Imatinib mesylate (Gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro
    Dziba, JM
    Ain, KB
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (05): : 2127 - 2135
  • [3] Imatinib Mesylate (Gleevec) Hepatotoxicity
    Ayse L. Mindikoglu
    Arie Regev
    Pablo A. Bejarano
    Enrique J. Martinez
    Lennox J. Jeffers
    Eugene R. Schiff
    Digestive Diseases and Sciences, 2007, 52 : 598 - 601
  • [4] Imatinib mesylate (Gleevec) hepatotoxicity
    Mindikoglu, Ayse L.
    Regev, Arie
    Bejarano, Pablo A.
    Martinez, Enrique J.
    Jeffers, Lennox J.
    Schiff, Eugene R.
    DIGESTIVE DISEASES AND SCIENCES, 2007, 52 (02) : 598 - 601
  • [5] Hypopigmentation from imatinib mesylate (Gleevec)
    Grossman, WJ
    Wilson, DB
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2004, 26 (03) : 214 - 214
  • [6] Imatinib Mesylate (Gleevec) induced hepatitis
    Rudraraju, M
    Chaudary, N
    Fazili, D
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (09): : S258 - S258
  • [7] Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines
    O Uziel
    E Fenig
    J Nordenberg
    E Beery
    H Reshef
    J Sandbank
    M Birenbaum
    M Bakhanashvili
    R Yerushalmi
    D Luria
    M Lahav
    British Journal of Cancer, 2005, 92 : 1881 - 1891
  • [8] Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines
    Uziel, O
    Fenig, E
    Nordenberg, J
    Beery, E
    Reshef, H
    Sandbank, J
    Birenbaum, M
    Bakhanashvili, M
    Yerushalmi, R
    Luria, D
    Lahav, M
    BRITISH JOURNAL OF CANCER, 2005, 92 (10) : 1881 - 1891
  • [9] Wnt/β-catenin signaling mediates antineoplastic effects of imatinib mesylate (Gleevec) in anaplastic thyroid cancer (Retraction of vol 91, pg 159, 2006)
    Rao, A. S.
    Kremenevskaja, N.
    von Wasielewski, R.
    Jakubcakova, V.
    Kant, S.
    Resch, J.
    Brabant, G.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (06): : 2118 - 2118
  • [10] Effects of Imatinib mesylate on the radio- and chemosensitivity of breast carcinoma cell lines
    Weigel, M. T.
    Weber, K.
    Maass, N.
    Jonat, W.
    Mundhenke, C.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2008, 68 : S31 - S31
12345